Mereo BioPharma (MREO) Cash from Operations (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Cash from Operations of 4312000.0 for Q1 2026, up 48.23% year-over-year from 2909010.85 in Q1 2025, and up 43.87% quarter-over-quarter from 7682000.0 in Q4 2025.
Mereo BioPharma (MREO) Cash from Operations (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Cash from Operations for 4 consecutive years, with 4312000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 48.23% year-over-year to 4312000.0; the TTM figure through Mar 2026 stood at 26954000.0 (up 18.74% YoY), while the FY2025 annual figure was 30971000.0, up 5.67% from the prior year.
- Cash from Operations climbed to 4312000.0 in Q1 2026 per MREO's latest filing, from 7682000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2659000.0 in Q3 2023 and bottomed at 9420000.0 in Q4 2024.
- Historically, Cash from Operations has averaged 6865307.69 across 4 years, with a median of 7682000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 382.78% — and 2026, when it surged 48.23%.
- Mereo BioPharma's Cash from Operations stood at 6789000.0 in 2023, then plunged by 38.75% to 9420000.0 in 2024, then rose by 18.45% to 7682000.0 in 2025, then jumped by 43.87% to 4312000.0 in 2026.
- Business Quant data shows MREO's Cash from Operations at 4312000.0 in Q1 2026, 7682000.0 in Q4 2025, and 7309000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -6.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.04 Mn |
| Jun 30, 2026 | -6.04 Mn |
| Mar 31, 2026 | -4.31 Mn |
| Mar 31, 2026 | -4.31 Mn |
| Dec 31, 2025 | -7.68 Mn |
| Dec 31, 2025 | -7.68 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Jun 30, 2025 | -7.65 Mn |
| Jun 30, 2025 | -7.65 Mn |
| Mar 31, 2025 | -8.33 Mn |
| Mar 31, 2025 | -8.33 Mn |
| Dec 31, 2024 | -9.42 Mn |
| Dec 31, 2024 | -9.42 Mn |
| Sep 30, 2024 | -7.52 Mn |
| Sep 30, 2024 | -7.52 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | -7.99 Mn |
| Mar 31, 2024 | -7.99 Mn |